X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/09/12/2513977/0/en/Mereo-BioPharma-Reports-Clinical-Update-and-Interim-Biomarker-Analysis-Presented-at-ESMO-2022-from-ACTIVATE-Phase-1b-2-Open-Label-Study-of-Etigilimab-Anti-TIGIT-Antibody-MPH-313-pl.html
https://www.globenewswire.com/news-release/2022/06/02/2455163/0/en/Mereo-BioPharma-To-Present-Data-Update-for-the-Phase-1b-2-Study-ACTIVATE-of-Etigilimab-and-Nivolumab-at-2022-ASCO-Annual-Meeting-Mereo-Also-Updates-Capital-Allocation-and-Portfolio.html
https://www.globenewswire.com/news-release/2022/05/26/2451674/0/en/Mereo-BioPharma-Announces-the-Presentation-of-Updated-Data-From-a-Phase-1b-2-Study-of-Etigilimab-as-a-Poster-at-the-2022-American-Society-of-Clinical-Oncology-Annual-Meeting.html
https://www.globenewswire.com/news-release/2020/10/19/2110294/0/en/Mereo-BioPharma-Announces-FDA-Clearance-to-Proceed-into-a-Phase-1b-2-study-for-Etigilimab-Anti-TIGIT.html
http://www.pmlive.com/pharma_news/celgene_says_no_to_mereos_cancer_drug_etigilimab_1291381
http://www.pmlive.com/pharma_news/celgene_says_no_to_mereos_cancer_drug_etigilimab_1291381
Market Place
Share 
